TY - JOUR T1 - NADPH–Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 12 LP - 23 DO - 10.1124/dmd.112.048991 VL - 41 IS - 1 AU - David S. Riddick AU - Xinxin Ding AU - C. Roland Wolf AU - Todd D. Porter AU - Amit V. Pandey AU - Qing-Yu Zhang AU - Jun Gu AU - Robert D. Finn AU - Sebastien Ronseaux AU - Lesley A. McLaughlin AU - Colin J. Henderson AU - Ling Zou AU - Christa E. Flück Y1 - 2013/01/01 UR - http://dmd.aspetjournals.org/content/41/1/12.abstract N2 - This is a report on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the Experimental Biology 2012 meeting in San Diego, California, on April 25, 2012. The symposium speakers summarized and critically evaluated our current understanding of the physiologic, pharmacological, and toxicological roles of NADPH–cytochrome P450 oxidoreductase (POR), a flavoprotein involved in electron transfer to microsomal cytochromes P450 (P450), cytochrome b5, squalene mono-oxygenase, and heme oxygenase. Considerable insight has been derived from the development and characterization of mouse models with conditional Por deletion in particular tissues or partial suppression of POR expression in all tissues. Additional mouse models with global or conditional hepatic deletion of cytochrome b5 are helping to clarify the P450 isoform- and substrate-specific influences of cytochrome b5 on P450 electron transfer and catalytic function. This symposium also considered studies using siRNA to suppress POR expression in a hepatoma cell–culture model to explore the basis of the hepatic lipidosis phenotype observed in mice with conditional deletion of Por in liver. The symposium concluded with a strong translational perspective, relating the basic science of human POR structure and function to the impacts of POR genetic variation on human drug and steroid metabolism. ER -